Suzuki, I., et. al. Evaluation of neurotoxicity for pesticide-related compounds in human iPS cell-derived neurons using microelectrode array. Toxicology In Vitro, 2023
Dominique Lessard leads corporate development at NeuCyte, overseeing outreach and strategic partnerships. Her expertise includes network growth and development, science communication, and science-driven advocacy.
Hui Liu, PhD, leads Drug Discovery R&D for NeuCyte's Epilepsy and Fragile X Syndrome programs. Before joining NeuCyte, Hui worked at Discovery Partners International, Biofocus-DPI, Nanosyn, and Dart NeuroScience.
Tao is NeuCyte’s president and CEO, overseeing management, corporate strategy, business development, finance, and drug discovery. He co-founded NeuCyte and previously practiced law, advising biotechnology and pharmaceutical companies and investors.
NeuCyte is an early-stage biotechnology company solely focused on neurological diseases. With expertise on advancing the drug discovery process by using cell based target-identification and drug-discovery platforms.